Brokerages forecast that Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) will report $180,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Eiger BioPharmaceuticals’ earnings. The lowest sales estimate is $100,000.00 and the highest is $260,000.00. The business is expected to issue its next earnings results on Friday, March 12th.

According to Zacks, analysts expect that Eiger BioPharmaceuticals will report full year sales of $180,000.00 for the current fiscal year, with estimates ranging from $100,000.00 to $260,000.00. For the next financial year, analysts anticipate that the company will report sales of $53.62 million, with estimates ranging from $3.99 million to $147.10 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Eiger BioPharmaceuticals.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.09.

A number of analysts have recently weighed in on EIGR shares. Zacks Investment Research raised Eiger BioPharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 11th. LADENBURG THALM/SH SH restated a “buy” rating and set a $28.00 target price on shares of Eiger BioPharmaceuticals in a research report on Tuesday, September 29th. Finally, BidaskClub raised Eiger BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $23.00.

Several institutional investors and hedge funds have recently made changes to their positions in EIGR. BlackRock Inc. grew its stake in shares of Eiger BioPharmaceuticals by 14.2% during the third quarter. BlackRock Inc. now owns 2,246,190 shares of the biotechnology company’s stock worth $18,283,000 after purchasing an additional 278,614 shares in the last quarter. Mangrove Partners grew its position in shares of Eiger BioPharmaceuticals by 15.2% during the third quarter. Mangrove Partners now owns 1,092,394 shares of the biotechnology company’s stock worth $8,892,000 after acquiring an additional 144,542 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of Eiger BioPharmaceuticals by 744.3% during the third quarter. Assenagon Asset Management S.A. now owns 555,181 shares of the biotechnology company’s stock worth $4,519,000 after acquiring an additional 489,426 shares during the last quarter. State Street Corp increased its holdings in shares of Eiger BioPharmaceuticals by 0.6% in the 3rd quarter. State Street Corp now owns 462,433 shares of the biotechnology company’s stock valued at $3,764,000 after acquiring an additional 2,568 shares during the period. Finally, P.A.W. Capital Corp raised its position in Eiger BioPharmaceuticals by 20.0% in the 3rd quarter. P.A.W. Capital Corp now owns 360,000 shares of the biotechnology company’s stock valued at $2,930,000 after purchasing an additional 60,000 shares during the last quarter. Institutional investors and hedge funds own 60.55% of the company’s stock.

EIGR stock traded up $0.03 during trading on Wednesday, hitting $11.36. The company had a trading volume of 367,312 shares, compared to its average volume of 532,416. The firm has a market capitalization of $369.56 million, a P/E ratio of -4.67 and a beta of 1.51. The company has a 50 day simple moving average of $10.31 and a 200-day simple moving average of $10.09. Eiger BioPharmaceuticals has a 52-week low of $4.55 and a 52-week high of $15.12. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.27.

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection.

Featured Story: How do analysts define an oversold condition?

Get a free copy of the Zacks research report on Eiger BioPharmaceuticals (EIGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.